Literature DB >> 31309982

Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps.

Larisa V Gubareva1, Alicia M Fry1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31309982      PMCID： PMC9012239          DOI： 10.1093/infdis/jiz245

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   7.759


× No keyword cloud information.
  13 in total

1.  The global spread of drug-resistant influenza.

Authors:  Dennis L Chao; Jesse D Bloom; Beth F Kochin; Rustom Antia; Ira M Longini
Journal:  J R Soc Interface       Date:  2011-08-24       Impact factor: 4.118

2.  In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Authors:  Takeshi Noshi; Mitsutaka Kitano; Keiichi Taniguchi; Atsuko Yamamoto; Shinya Omoto; Keiko Baba; Takashi Hashimoto; Kayo Ishida; Yukihiro Kushima; Kazunari Hattori; Makoto Kawai; Ryu Yoshida; Masanori Kobayashi; Tomokazu Yoshinaga; Akihiko Sato; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Takao Shishido; Akira Naito
Journal:  Antiviral Res       Date:  2018-10-11       Impact factor: 5.970

3.  Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.

Authors:  Takeki Uehara; Frederick G Hayden; Keiko Kawaguchi; Shinya Omoto; Aeron C Hurt; Menno D De Jong; Nobuo Hirotsu; Norio Sugaya; Nelson Lee; Keiko Baba; Takao Shishido; Kenji Tsuchiya; Simon Portsmouth; Hiroshi Kida
Journal:  J Infect Dis       Date:  2020-01-14       Impact factor: 5.226

Review 4.  Current and novel antiviral strategies for influenza infection.

Authors:  Hui-Ling Yen
Journal:  Curr Opin Virol       Date:  2016-06-23       Impact factor: 7.090

5.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Authors:  Frederick G Hayden; Norio Sugaya; Nobuo Hirotsu; Nelson Lee; Menno D de Jong; Aeron C Hurt; Tadashi Ishida; Hisakuni Sekino; Kota Yamada; Simon Portsmouth; Keiko Kawaguchi; Takao Shishido; Masatsugu Arai; Kenji Tsuchiya; Takeki Uehara; Akira Watanabe
Journal:  N Engl J Med       Date:  2018-09-06       Impact factor: 91.245

6.  Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.

Authors:  Justin D Hoopes; Elizabeth M Driebe; Erin Kelley; David M Engelthaler; Paul S Keim; Alan S Perelson; Libin Rong; Gregory T Went; Jack T Nguyen
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

7.  Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.

Authors:  John H Beigel; Yajing Bao; Joy Beeler; Weerawat Manosuthi; Alex Slandzicki; Sadia M Dar; John Panuto; Richard L Beasley; Santiago Perez-Patrigeon; Gompol Suwanpimolkul; Marcelo H Losso; Natalie McClure; Dawn R Bozzolo; Christopher Myers; H Preston Holley; Justin Hoopes; H Clifford Lane; Michael D Hughes; Richard T Davey
Journal:  Lancet Infect Dis       Date:  2017-09-22       Impact factor: 25.071

8.  Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.

Authors:  Shinya Omoto; Valentina Speranzini; Takashi Hashimoto; Takeshi Noshi; Hiroto Yamaguchi; Makoto Kawai; Keiko Kawaguchi; Takeki Uehara; Takao Shishido; Akira Naito; Stephen Cusack
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

9.  Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.

Authors:  Emi Takashita; Chiharu Kawakami; Rie Ogawa; Hiroko Morita; Seiichiro Fujisaki; Masayuki Shirakura; Hideka Miura; Kazuya Nakamura; Noriko Kishida; Tomoko Kuwahara; Akira Ota; Hayato Togashi; Ayako Saito; Keiko Mitamura; Takashi Abe; Masataka Ichikawa; Masahiko Yamazaki; Shinji Watanabe; Takato Odagiri
Journal:  Euro Surveill       Date:  2019-03

10.  Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Authors:  Brendan Flannery; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Melissa A Rolfes; Sarah Spencer; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 20.999
View more
  6 in total

1.  A Dual-Functioning 5'-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1.

Authors:  Neetu Singh; Priya Ranjan; Weiping Cao; Jenish Patel; Shivaprakash Gangappa; Bruce A Davidson; John M Sullivan; Paras N Prasad; Paul R Knight; Suryaprakash Sambhara
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-31       Impact factor: 8.886

2.  Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.

Authors:  Chiara Medaglia; Arnaud Charles-Antoine Zwygart; Paulo Jacob Silva; Samuel Constant; Song Huang; Francesco Stellacci; Caroline Tapparel
Journal:  Microorganisms       Date:  2021-06-01

Review 3.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

4.  Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.

Authors:  Mina Nakauchi; Emi Takashita; Seiichiro Fujisaki; Masayuki Shirakura; Rie Ogawa; Hiroko Morita; Hideka Miura; Shinji Saito; Shinji Watanabe; Takato Odagiri; Tsutomu Kageyama
Journal:  Influenza Other Respir Viruses       Date:  2020-02-16       Impact factor: 4.380

Review 5.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

Authors:  Kimiyasu Shiraki; Tohru Daikoku
Journal:  Pharmacol Ther       Date:  2020-02-22       Impact factor: 12.310

6.  Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study.

Authors:  Yu-Hsiang Hsieh; Andrea F Dugas; Frank LoVecchio; Breana McBryde; Erin P Ricketts; Kathryn Saliba-Shaw; Richard E Rothman
Journal:  Influenza Other Respir Viruses       Date:  2020-10-02       Impact factor: 4.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.